A Study for Outpatients With COVID-19: Activ-2
Partner

ACTIV-2: Outpatient Monoclonal Antibodies and Other Therapies

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)


The ACTIV-2 Study is testing different medicines to see if they are safe and can help adults with COVID-19. Finding treatments for COVID-19 is important because the virus is spreading quickly all over the world and can cause serious sickness and even death.

About 
COVID-19

Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.

How is this study designed?

Study type: Interventional (Clinical Trial) Estimated Enrollment: 2000 participants Actual Study Start Date: August 19, 2020 Estimated Study Completion Date: February 2021

Researchers want to see if the medicines are:

  • Safe
  • Can help people get better faster
  • Can get rid of the virus
  • Can keep people from getting sicker
  • Can prevent people from having to go to the hospital

Be Part of the Solution

Who is this study for?

The ACTIV-2 Study is for adults 18 years and older who:

  • Tested positive for COVID-19 (not more than 7 days ago)
  • Have COVID-19 symptoms
  • Are at home (not in the hospital)

What should I expect?

The study lasts about 6 months. You will have in person visits to check on the status of your health. Most of these visits will happen during the first month of the study. You will also have phone calls or video chats from your home with a researcher.

Activ-2 covid study application image

Visit information

1

Permission

If you agree to be in the study, you will give your permission by signing an informed consent form.

The informed consent contains all of the important information about the study. Ask questions and make sure you understand the study before signing the form.

2

Screening

You will answer some questions to make sure the study is right for you.

The screening may take place during a visit with a researcher, over the phone, or by video chat. If you meet with the researcher, you may also have a checkup.

3

Entry visit

You will meet with a researcher for tests and to be placed in a treatment group.

You will have some tests to check your heart, lungs, and general health, as well as a blood test and a nose swab. You will be placed in a treatment group by chance, like flipping a coin.

4+

Treatment and clinic visits

Take the medicine exactly as the researcher explains to you. You will also have up to 7 visits with a researcher for tests and up to 5 phone calls from home with the researcher or nurse. Most of the visits happen during the first 28 days of the study.

How do I enroll in the study?

Have you been diagnosed with COVID-19 in the past week? If so, you may be a good fit to join the ACTIV-2 Study and help us find a treatment for COVID-19! Call to learn more (877) 345-8813. Being in the study is completely voluntary. You can leave the study at any time.

For general questions about COVID-19 clinical trials, please email [email protected]